Research

Hormonal

Genetic variation in the NBEA gene predicts weight loss response to GLP-1 receptor agonists (GLP-1RAs), with specific NBEA scores identifying individuals likely to be highly responsive or non-responsive to treatment.

If you are prescribed a GLP-1RA like semaglutide or liraglutide, ask your doctor about genetic testing for the NBEA gene. This test can predict whether you are likely to lose significant weight (top 20% responders) or not respond at all. This helps avoid wasting time and money on medications that are unlikely to work for your specific biology, allowing for a more personalized and effective obesity treatment plan.

GoodQualifiesHIGH confidence
These findings indicate that NBEA genetic variation is predictive of GLP-1RA weight loss and may support future efforts to identify individuals likely to experience significant weight loss with GLP-1RAs, enabling personalised obesity treatment strategies.
Arshiya Mariam et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Large real-world cohorts (NIH All of Us N=6556, UK Biobank N=241) with independent validation, though observational in nature.

Source

Neurobeachin ( <scp> <i>NBEA</i> </scp> ) is a novel gene associated with <scp>GLP</scp> ‐1 receptor agonist associated weight loss

Arshiya Mariam et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16612

cohort · n=7056Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →